The phase 3b STEP UP obesity trial in more than 1,400 patients compared a 7.2mg weekly subcutaneous injection of semaglutide to the standard 2.6mg weekly dose sold as Wegovy or a matched placebo over 72 weeks
It belongs to a category of compounds that have not completed the standard FDA approval process, yet have attracted significant interest from wellness influencers and some physicians
The Numbers: Injectable tirzepatide: Nearly 100% bioavailability (all medication reaches bloodstream) Oral peptides without enhancement: Less than 1% bioavailability This means youd need 100 times more medication in oral form to match injection effectiveness Technical Barriers: Creating an oral version requires solving multiple problems: Protecting the peptide from stomach acid Preventing breakdown by digestive enzymes Getting the large molecule through intestinal walls Maintaining therapeutic drug levels Doing all this at a reasonable cost Current Development Status: Eli Lilly has not publicly announced advanced clinical trials for oral tirzepatide
In patients with McCune-Albright syndrome or pigmentary mosaicism of other etiologies, CALMs may have a segmental distribution with sharp midline demarcation and an irregular, jagged outline (coast of Maine)
Responsibility: Commitment to sustainable practices and ethical conduct
Shay Siegel es una autora de literatura juvenil, escritora independiente y editora de Long Island, Nueva York